Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SinnoTest for Biotherapy Prediction in RA
NCT04117165Withdrawn
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Clinical benefit of using SinnoTest® software at 6 months. Planned start Mar 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT04117165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117165.